[New flu therapy. Progress or burden for the budget?].
Vogel
G E
GE
Arzt für Innere Medizin, Gastroenterologie/Nephrologie, München.
D000081:Acetamides / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D006146:Guanidines; D006801:Humans; D007251:Influenza, Human / Q000188:drug therapy* / Q000191:economics; D009439:Neuraminidase / Q000037:antagonists & inhibitors; D053139:Oseltamivir; D011714:Pyrans; D012794:Sialic Acids / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D053243:Zanamivir
D000081:Acetamides; D000998:Antiviral Agents; D006146:Guanidines; D011714:Pyrans; D012794:Sialic Acids; D053139:Oseltamivir; D009439:Neuraminidase; D053243:Zanamivir